I Lead 2 Archives - Sidra Medicine

Karunakaran Ramaswamy

Dr. Ramaswamy is an anesthesiologist specializing in pain relief during labor and providing safe anesthesia for surgery. Safety and patient comfort are his priority. He has more than 20 years’ experience and trained in Oxford and India. Dr. Ramaswamy joined Sidra Medicine in October 2017 and was part of the team that helped open the hospital safely. Dr. Ramaswamy frequently receives excellent feedback from patients and staff.

18 March, 2025

Sidra Medicine and İzmir Biomedicine and Genome Center (IBG) Sign MoU to Advance Pediatric Biomedical Research

Sidra Medicine, a member of Qatar Foundation, has signed a Memorandum of Understanding (MoU) with the İzmir Biomedicine and Genome Center (IBG) to enhance collaboration in pediatric biomedical research. The agreement marks a significant milestone in fostering scientific research, innovation, and knowledge exchange between the two institutions.

11 March, 2025

Sidra Medicine Study Identifies New Non-Invasive Method for Detecting Heart Disease Risk

Sidra Medicine, a member of Qatar Foundation, has published a study in Scientific Reports, a journal from Nature Portfolio titled "Distinctive Blood and Salivary Proteomics Signatures in Qatari Individuals at High Risk for Cardiovascular Disease". The study identifies protein markers that can help detect individuals at high risk of cardiovascular disease. These non-invasive methods contribute to advancing personalized healthcare and facilitating early diagnosis.

04 March, 2025

Sidra Medicine’s ENT Service Delivers Breakthrough in Airway Surgery

Sidra Medicine, a member of Qatar Foundation, is setting a new benchmark in pediatric healthcare with Qatar’s only national pediatric tracheostomy program. Supporting over 150 patients annually, the program has become a vital resource for families in Qatar, offering cutting-edge care and life-changing outcomes.

25 February, 2025

Sidra Medicine and Rasmal Ventures Partner to Drive Digital Health Innovation in Qatar

Sidra Medicine, a member of Qatar Foundation, has signed a Memorandum of Understanding (MOU) with Rasmal Ventures, Qatar’s first venture capital firm. The strategic partnership, announced at the Web Summit Qatar 2025, marks a significant step in the hospital’s role in supporting and advancing digital health innovation in Qatar and beyond.

18 February, 2025

Sidra Medicine Partners with LGA Group to Enhance Healthcare Accessibility

Sidra Medicine, a member of Qatar Foundation, has signed a contractual agreement with LGA Assistance Group, a global leader in medical insurance services in the region.

18 February, 2025

Msheireb Museums and Sidra Medicine Kickstart 2025 Science Café Series

Following a successful inaugural year, Msheireb Museums, in partnership with Sidra Medicine, conducted the first session of their 2025 Science Café Series. Titled “Nurturing Health: Our Microbiome and AI-Driven Insights for Wellness,” the session, held on Monday, attracted a large audience at Bin Jelmood House, in Msheireb Downtown Doha.

12 February, 2025

Sidra Medicine Honoured with Award-Winning Imaging Achievement

Sidra Medicine, a member of Qatar Foundation, was recently honored with the BRIO-8 Award1 from Qatar Research, Development and Innovation (QRDI) Council. BRIO, which stands for ‘Best Representative Image of an Outcome’ is a competition that provides a bridge between art and science to showcase stimulating images that represent outcomes of QRDI funded research.

05 February, 2025

Sidra Medicine Celebrates Graduates of Certificate in Leadership Program at Georgetown University in Qatar

In a closing ceremony at Georgetown University in Qatar (GU-Q), Sidra Medicine celebrated the achievements of 14 middle and senior managers who completed the newly launched Strategic Leadership Development Certificate Program offered by Georgetown University.

28 January, 2025

Sidra Medicine Establishes Gene Therapy Center for Pediatric Rare Diseases

Sidra Medicine, a member of Qatar Foundation, has established a Gene Therapy Center to treat rare genetic diseases such as Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD).